You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-Anaplastic Lymphoma Kinase (ALK)-TPX 0005
TPX 0005

Chemical Structure : TPX 0005

CAS No.: 1802220-02-5

TPX 0005 (Ropotrectinib;Repotrectinib;TPX0005)

Catalog No.: PC-62298Not For Human Use, Lab Use Only.

TPX 0005 (Ropotrectinib) is a novel ALK/ROS1/TRK inhibitor, effectively inhibits a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants.

Packing Price Stock Quantity
10 mg $128 In stock
25 mg $228 In stock
50 mg $398 In stock
100 mg $598 In stock
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

TPX 0005 (Ropotrectinib, Repotrectinib, TPX0005) is a novel ALK/ROS1/TRK inhibitor, effectively inhibits a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants.
Repotrectinib (TPX-0005) potently inhibits WT ALK (IC50=1.01 nM) and mutant ALKs including ALK G1202R (IC50=1.26 nM) and ALK L1196M (IC50=1.08 nM).
Repotrectinib (TPX-0005) is also a potent SRC inhibitor (IC50=5.3 nM); shows low nano-molar activities against CD74-ROS1 G2032R (IC50=8.4 nM), LMNA-TRKA G595R (IC50=0.4 nM),TEL-TRKB G639R (IC50=1.9 nM) and TEL-TRKC G623R (IC50=0.4 nM) in Ba/F3 cell proliferation assays; dramatically causes tumor growth inhibition and tumor regression in xenograft tumor model.
Repotrectinib (TPX-0005) demonstrates desired druglike properties and good safety profile.

Physicochemical Properties

M.Wt 355.373
Formula C18H18FN5O2
Appearance Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(7S,13R)-11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-1,15-etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one

References

1. Zhai D, et al. DOI: 10.1158/1538-7445.AM2016-2132 Published July 2016

2. J.J. Cui, et al. DOI: http://dx.doi.org/10.1016/S0959-8049(16)32675-2.

3. Drilon A, et al. Cancer Discov. 2018 Aug 9. pii: CD-18-0484.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: